GSK1349572 Relative Bioavailability Study

NCT01098513 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG: GSK1349572 formulation AP
DRUG: GSK1349572 formulation AW
DRUG: GSK1349572 formulation AX

Sponsor

ViiV Healthcare

Collaborators

[object Object]